Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$74.76 USD

74.76
485,354

-0.88 (-1.16%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $74.82 +0.06 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

NextGen's Medfusion Buyout to Improve Patient Experience

by Zacks Equity Research

NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Conmed (CNMD) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Conmed (CNMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.

Conmed (CNMD) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 10.71% and 2.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) raises 2019 revenue and earnings per share guidance.

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.

Cerner (CERN) Set to Improve Patient Experience With New Deal

by Zacks Equity Research

The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.

Here's Why You Should Hold Onto Cerner (CERN) Stock for Now

by Zacks Equity Research

Cerner (CERN) keeps its 2019 revenue guidance intact; expects improvement in bookings.

Here's Why You Should Hold on to Wright Medical (WMGI) Stock

by Zacks Equity Research

Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Fresenius Medical Launches 4008A Dialysis Machine in China

by Zacks Equity Research

Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

PRA Health Simplifies Treatment Decisions With Metys Launch

by Zacks Equity Research

PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.

Here's Why You Should Retain Pacific Biosciences For Now

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.

Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

by Zacks Equity Research

Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set

by Zacks Equity Research

HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.

Here's Why You Should Retain OPKO Health (OPK) Stock For Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.

Here's Why You Should Retain Patterson Companies (PDCO) Now

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to Ecolab (ECL) Stock Now

by Zacks Equity Research

Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.

Masimo (MASI) Boosts O3 Platform With Three New Indices

by Zacks Equity Research

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.